HEMEX closes an oversubscribed Series C financing round

Please login or
register
10.02.2021
symbolic picture health

HEMEX, a bench-to-market Life Science consulting services- and investment firm, supported more than 30 companies in 2020 and has built offices in Europe, USA and Asia. The firm has closed an oversubscribed Series C financing round with significant contributions from Swiss entrepreneurs and private investors to accelerate its growth further.

HEMEX was founded in 2015 in Liestal, as a consulting company deviated to supporting innovative life science start-ups in bringing state-of-the-art technologies to market. Backed by a team with expertise and knowledge in innovative pharmaceuticals, medical devices, in-vitro diagnostics, and digital health applications, both in human and animal health (“One Health”), the company offers all services required to bring lead products to the market, especially throughout the Clinical Development phase (clinical trials, regulatory affairs, quality assurance). It also provides top-notch infrastructure such as office and lab space, years of development expertise, and access to a global network of dedicated early-stage co-investors. 

Additionally, the company supports start-ups financially through investments in early-stage financing rounds. The company also takes an active role in the due diligence and subsequent management of the company through board roles and executive leadership support. Over 30 companies have obtained support from HEMEX including Annaida Technologies, Artidis, Aspivix, Ender Diagnostics, HiD Imaging.

In 2017, HEMEX opened a subsidiary in Germany and 2018 in the USA. In 2019, the company signed an exclusive partnership in China’s Henan province and is now furthering its global expansion with additional locations in Orlando, FL, and Singapore. To accelerate this growth, HEMEX has obtained fresh capital from Swiss entrepreneurs and private investors. The company will use the funds to strengthen its team, increase service offerings, and accelerate its global expansion.

Pascal Winnen, CEO of HEMEX, commented: “We anticipate another year of strong growth for healthcare, both domestically and on a global level. We will continue to attract top talent from world-class universities, with great new employees joining the HEMEX team and through the support of innovative Life Science start-ups. This vote of confidence for our business model from a group of successful entrepreneurs confirms that HEMEX is on the right track for substantial future success.” 

(Press release/RAN)

0Comments

rss